Shionogi Highlights Real-World Effectiveness of Fetroja/Fetcroja Against MBL-Producing Enterobacterales at ESCMID Global 2026
Shionogi & Co., Ltd. has unveiled new real-world and surveillance data highlighting the clinical utility of cefiderocol (marketed as Fetroja®/Fetcroja®) in the treatment of highly resistant Gram-negative bacterial infections. The findings were presented at the European Society of Clinical Microbiology and Infectious Diseases Congress 2026, held in Munich from April 17 to 21, 2026, one of the world’s leading forums for infectious disease research and antimicrobial resistance (AMR) discussions.
The newly presented data provide important insights into the real-world effectiveness, safety, and microbiological performance of cefiderocol, particularly in infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales—pathogens that are among the most difficult to treat due to their extensive resistance to commonly used antibiotics.
Cefiderocol is a novel siderophore cephalosporin antibiotic designed to overcome resistance mechanisms in Gram-negative bacteria. It utilizes a “Trojan horse” strategy, binding to iron and exploiting bacterial iron transport systems to gain entry into the cell, thereby bypassing resistance pathways that often render other antibiotics ineffective. The drug is currently approved for the treatment of serious infections in adults, including complicated urinary tract infections (cUTIs) and hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-negative organisms.
Real-World Evidence from the CIRCE Study
A key highlight of the data presented at the congress was the CIRCE study, a retrospective, observational, multicenter chart review conducted across Spain between January 2023 and April 2025. The study evaluated 232 adult patients with confirmed infections caused by MBL-producing Enterobacterales, offering valuable real-world evidence on the use of cefiderocol in routine clinical practice.
The patient population in the CIRCE study represented a highly complex and critically ill group. At baseline, 29% of patients were immunocompromised, 27% were admitted to intensive care units, and 13% presented with septic shock—conditions that are typically associated with high morbidity and mortality. These characteristics underscore the severity of infections being treated and the limited therapeutic options available in such cases.
Despite these challenges, the outcomes observed in the study were encouraging. At day 14, 68% of patients treated with cefiderocol were considered clinically cured, while 82% achieved a clinical response, indicating either full resolution or significant improvement of infection-related symptoms. Survival rates were also notable, with 90% of patients alive at day 14 and 83% at day 28.
In terms of safety, adverse events associated with cefiderocol were collected through routine chart reviews. The analysis did not identify any new safety signals beyond the drug’s established safety profile, reinforcing its tolerability in a real-world setting.
Addressing the Challenge of MBL-Producing Pathogens
MBL-producing Enterobacterales represent a major global health threat due to their ability to inactivate nearly all beta-lactam antibiotics, including carbapenems, which are often reserved as last-line treatments for severe infections. This resistance significantly limits therapeutic options and is associated with poor clinical outcomes.
Within the CIRCE study, the most commonly identified pathogens were carbapenem-resistant Klebsiella pneumoniae and Enterobacter species. Both are classified by the World Health Organization as critical priority pathogens due to their high levels of resistance and the urgent need for new treatment options.
The study also reported microbiological eradication rates among patients with follow-up cultures. These rates were 85% for bloodstream infections and 82% for urinary tract infections, indicating that cefiderocol was effective not only in improving clinical symptoms but also in eliminating the causative pathogens.
Approximately half of the patients in the study received cefiderocol based on susceptibility testing, highlighting the importance of diagnostic tools in guiding targeted antimicrobial therapy. This approach aligns with antimicrobial stewardship principles, which emphasize the use of appropriate, evidence-based treatments to minimize resistance development.
Dr. Ricard Ferrer, Head of the Intensive Care Department at Vall d’Hebron Hospital in Barcelona, emphasized the significance of these findings. He noted that infections caused by MBL-producing Enterobacterales are a growing clinical challenge worldwide, particularly among critically ill patients. According to Dr. Ferrer, the CIRCE data provide meaningful evidence supporting the clinical effectiveness of cefiderocol and its role in addressing this unmet medical need.
Long-Term Surveillance Data: Stability Against Resistance
In addition to the CIRCE study, Shionogi presented data from in vitro surveillance programs evaluating cefiderocol’s activity against Stenotrophomonas maltophilia, an opportunistic Gram-negative pathogen known for its intrinsic resistance to multiple antibiotic classes.
The analysis included more than 4,000 clinical isolates collected over a 10-year period through the SIDERO-WT (2014–2019) and SENTRY (2020–2024) surveillance programs. Importantly, the data showed no significant change in cefiderocol susceptibility before and after its market introduction. This finding suggests that resistance to cefiderocol has not emerged at a meaningful level over time, an encouraging signal in the context of global AMR concerns.
Stenotrophomonas maltophilia is particularly problematic in high-risk populations, such as immunocompromised patients and those in intensive care units, where treatment options are often limited. The stability of cefiderocol’s activity against this pathogen underscores its potential as a reliable therapeutic option in difficult-to-treat infections.
Clinical Outcomes from the PROVE Study
Further supporting evidence was presented from the PROVE study, which included a subgroup analysis of 119 patients with Stenotrophomonas maltophilia infections. The results demonstrated clinical cure in approximately two-thirds of patients, many of whom were critically ill and receiving care in intensive care settings.
These findings reinforce cefiderocol’s effectiveness across a range of resistant pathogens and clinical scenarios, highlighting its versatility as a treatment option in modern infectious disease management.
The Broader Context: Combating Antimicrobial Resistance
The data presented at ESCMID 2026 come at a time when antimicrobial resistance is widely recognized as one of the most pressing global health challenges. The increasing prevalence of multidrug-resistant Gram-negative bacteria threatens to undermine decades of progress in modern medicine, making it more difficult to treat common infections and perform routine medical procedures safely.
Mark Hill, Global Head of Medical Affairs at Shionogi, emphasized the importance of continued innovation in this field. He noted that the growing body of evidence supporting cefiderocol highlights its potential role in addressing resistant infections, while also underscoring the need for sustained investment in antimicrobial research and development.
Hill also pointed out that generating robust clinical and real-world evidence is essential for informing treatment decisions and optimizing patient outcomes. By contributing data from diverse sources, including observational studies and surveillance programs, Shionogi aims to support healthcare providers in making evidence-based choices in complex clinical situations.
The comprehensive data presented by Shionogi at the European Society of Clinical Microbiology and Infectious Diseases Congress 2026 provide compelling evidence for the effectiveness and safety of cefiderocol in treating highly resistant Gram-negative infections. From real-world outcomes in the CIRCE study to long-term surveillance data and clinical results from the PROVE study, the findings collectively demonstrate the drug’s potential to address critical gaps in current treatment options.
As antimicrobial resistance continues to evolve, therapies like cefiderocol represent an important advancement in the fight against difficult-to-treat infections. By combining innovative mechanisms of action with strong clinical evidence, cefiderocol offers a promising solution for patients facing life-threatening bacterial diseases, particularly those caused by pathogens with limited or no effective treatment alternatives.
Through ongoing research, collaboration, and investment, companies like Shionogi are playing a vital role in advancing the global response to antimicrobial resistance—helping to ensure that effective treatments remain available for future generations.
Source Link:https://www.businesswire.com/
